Morgan Stanley Codiak Bio Sciences, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.18 - $0.81 $309 - $1,390	-1,717 Reduced 10.07%	15,334 $2,000
Q4 2022 Feb 14, 2023	SELL	$0.32 - $0.9 $5,135 - $14,443	-16,048 Reduced 48.48%	17,051 $6,000
Q3 2022 Nov 14, 2022	BUY	$0.82 - $3.19 $1,224 - $4,762	1,493 Added 4.72%	33,099 $26,000
Q2 2022 Oct 27, 2022	BUY	$2.24 - $6.96 $16,009 - $49,743	7,147 Added 29.22%	31,606 $90,000
Q2 2022 Aug 15, 2022	BUY	$2.24 - $6.96 $16,009 - $49,743	7,147 Added 29.22%	31,606 $90,000
Q1 2022 Oct 27, 2022	SELL	$4.3 - $12.95 $30,732 - $92,553	-7,147 Reduced 22.61%	24,459 $153,000
Q1 2022 May 13, 2022	BUY	$4.3 - $12.95 $8,307 - $25,019	1,932 Added 8.58%	24,459 $153,000
Q4 2021 Feb 14, 2022	SELL	$10.0 - $16.78 $99,200 - $166,457	-9,920 Reduced 30.57%	22,527 $251,000
Q3 2021 Nov 15, 2021	BUY	$15.58 - $22.88 $505,524 - $742,387	32,447 New	32,447 $529,000

238K

Ticker CDAK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,995,200
Market Cap $360K
Description
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.